Current perspectives on vaccines and therapeutics for Lassa Fever

Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment...

Full description

Saved in:
Bibliographic Details
Published in:Virology journal 2024-12, Vol.21 (1), p.320
Main Authors: Warner, Bryce M, Safronetz, David, Stein, Derek R
Format: Article
Language:English
Subjects:
Africa, Western - epidemiology
Animals
Antiviral Agents - therapeutic use
Care and treatment
Climatic changes
Clinical Trials as Topic
Development and progression
Humans
Lassa fever
Lassa Fever - immunology
Lassa Fever - prevention & control
Lassa Fever - therapy
Lassa virus - immunology
Marburg virus disease
Monoclonal antibodies
Review
Vaccine Development
Vaccines
Viral Vaccines - immunology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks. Several candidate vaccines have received support and have entered clinical trials with promising early results. This review focuses on the current state of vaccine and therapeutic development for LASV disease and the potential of these interventions to advance through clinical trials. The growing burden of LASV disease in Africa highlights the importance of advancing preclinical and clinical testing of vaccines and therapeutics to respond to the growing threat of LASV disease.
ISSN:1743-422X
1743-422X
DOI:10.1186/s12985-024-02585-7